Zymeworks grabs Theravance in $929 million respiratory buyout
Zymeworks has closed its $929 million takeover of Theravance Biopharma, picking up a commercial COPD drug and a set of royalty streams that reshape its revenue mix.
BeOne Medicines 1 article
The company-level identity of BeOne Medicines is anchored in oncology therapeutics and zanubrutinib B-cell malignancy therapy, reflecting an oncology biopharmaceutical company with a defined therapeutic focus. The biotechnology scope of BeOne Medicines spans monoclonal antibody cancer therapy, B-cell receptor signaling inhibition and combination cancer therapeutics; these features distinguish BeOne Medicines within its disease and mechanism context. For BeOne Medicines, BTK inhibitor development is retained as a stable scientific attribute, while named products and targets remain separate entities.